Dan Schell articles
-
Life Sciences CEOs Assess Upcoming Business Risk
6/1/2021
We take a closer look at the data related to organizational growth risks included in a recent KPMG “Global CEO Outlook” survey.
-
CEO Q&A: Dr. Aoife Brennan
5/3/2021
Dr. Aoife Brennan, president and CEO of Synlogic, discusses how the pandemic has affected her company’s operations and clinical trials.
-
A Q&A With A COVID-Era New CEO
5/3/2021
David Horn Solomon, Ph.D., took on the role of CEO of Pharnext in April 2020, at the beginning of the pandemic and just after the company had seen it’s Phase 3 trial data rejected by the FDA.
-
A Q&A With Bernie Zeiher Of Astellas
4/1/2021
Bernie Zeiher Of Astellas took on the dual role of CMO & President of Development in April 2018. Here he discusses how he adjusted to that job and some of the best practices he’s learned along the way.
-
CEO Q&A: Mary Szela
2/1/2021
Mary Szela spent 25 years in Big Pharma and the last 7 at three small biotechs. The CEO Of TriSalus Life Sciences discusses how she adapted during these career changes and some of the difficulties she encountered along the way.
-
Program Strives For More Females On Pharma Boards
11/1/2019
In this first of a series of articles dedicated to the Women in Bio Boardroom Ready program, we discuss what the program entails and feedback from some previous participants.
-
How To Avoid Data-Integrity Woes In Pharma
11/1/2019
This article discusses what should be addressed to mitigate enterprise risks as they pertain to data integrity. It also lists what data-integrity compliance issues you should assess when choosing a CDMO.
-
Program Winners Look Back On Year Of Change
10/1/2019
Laura Indolfi and Elizabeth O’Day discuss how being chosen for the Massachusetts Next Generation Initiative (MassNextGen) changed their respective biopharma companies.
-
A Second Career As A Biotech CEO
8/1/2019
“This was a real turnaround type of challenge, and I knew it was going to be a steep learning curve for me,” says Steven Yatomi-Clarke of Prescient Therapeutics. “In fact, at the time, I probably underestimated the amount of work it was going to take to get the company up to scratch.”
-
Support For Women-Led Early-Stage Life Sciences Companies
7/17/2019
A preview of an October 2109 issue article that discusses the results of the 2018 MassNextGen initiative that provides funding and coaching support to early-stage life sciences companies started by females.